A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
NCT07220564
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Haemophilia A
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 64 years
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- Novo Nordisk A/S
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- UC Denver Hemoph & Thrombo Ctr · Aurora, CO
Indiana · 1
- Indiana Hemophilia-Thromb Ctr · Indianapolis, IN
Iowa · 1
- University of Iowa_Iowa City · Iowa City, IA
Pennsylvania · 2
- Penn State MS Hershey Med Ctr · Hershey, PA
- St Christopher Hosp for Child · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.